US OptionsDetailed Quotes
GOSS250516C500
- 0.40
- 0.000.00%
15min DelayTrading Apr 28 10:54 ET
0.00High0.00Low
0.00Open0.40Pre Close0 Volume37 Open Interest0.50Strike Price0.00Turnover0.00%IV-7.22%PremiumMay 16, 2025Expiry Date0.47Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Gossamer Bio Stock Discussion
Sign in to post a comment
$Gossamer Bio (GOSS.US)$ Anyone have any thoughts on this stock
2
1
$Gossamer Bio (GOSS.US)$ Anybody here
3
$Gossamer Bio (GOSS.US)$ Massive Volume for this one
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
loading...
2
$Gossamer Bio (GOSS.US)$
Really like the daily chart here. On watch for sure and might take a position tomorrow.
Really like the daily chart here. On watch for sure and might take a position tomorrow.
1
$Gossamer Bio (GOSS.US)$
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Tuesday, 28th January at 7:01 am
- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH -
Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Tuesday, 28th January at 7:01 am
- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH -
Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...
3
$Gossamer Bio (GOSS.US)$ Holding up good vrs the bears very good sign.
1
No comment yet
BelleWeather : I have a small position in LEAPS calls (though sold half today.) Like all biopharma, seems promising but is risky.